Chiusura precedente | 2,5100 |
Aperto | 2,4700 |
Denaro | 2,4500 x 4000 |
Lettera | 2,5400 x 3200 |
Min-Max giorno | 2,4700 - 2,6450 |
Intervallo di 52 settimane | 1,0100 - 2,6450 |
Volume | |
Media Volume | 2.627.766 |
Capitalizzazione | 500,71M |
Beta (5 anni mensile) | 1,02 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -0,4900 |
Prossima data utili | 08 nov 2022 - 14 nov 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 4,67 |
2Q2022 Total Revenues Were $33.9 Million, a 90% Y-o-Y Increase Grew 2Q2022 Gross Profit to $7.8 Million, Up 112% Over 1Q2022 Narrowed 2Q2022 Net Losses to $13.8 Million, a 45% Improvement Over 1Q2022 Full Year 2022 Total Revenues Expected to Exceed $130 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA)
Conference Call Scheduled for August 10, 2022, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it will report financial results for the second quarter ended June 30, 2022, on Wednesday, August 10, 2022, after the U.S. financial markets clos
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that the Company will be added to the Russell 2000® Index, effective as of market open on June 27, 2022, according to a preliminary list of additions posted by FTSE Russell on June 17, 2022. The Russell 2000® Ind